CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab

Miyazaki, Kana; Yamaguchi, Motoko; Suzuki, Ritsuro; Kobayashi, Yasuhito; Maeshima, Akiko Miyagi; Niitsu, Nozomi; Ennishi, Daisuke; Tamaru, Jun Ichi; Ishizawa, Kenichi; Kashimura, Masamichi; Kagami, Yoshitoyo; Sunami, Kazutaka; Yamane, Hiromichi; Nishikori, Momoko; Kosugi, Hiroshi; Yujiri, Toshiaki; Hyo, Rie; Katayama, Naoyuki; Kinoshita, Tomohiro; Nakamura, Shigeo

doi:10.1093/annonc/mdq627

Cited by 111 publications

(133 citation statements)

References 22 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…The surface or cytoplasmic light-chain evaluation was the most useful parameter in identifying a B-cell lymphoma, whereas CD5 and CD10 are useful in identifying the different subtypes (1). However, their specificity is not absolute on neoplastic cells, as stands out from data also reported by us in Table 4; in fact they may be absent in FL (CD10 À FL) (37) or can be unexpectedly expressed elsewhere, such as CD5 on some SMZL cases (5,49) and FL (36,39,50,51), CD10 on SLL (50,51), NMZL (43), MCL and MALT (37), and HCL (52), CD5/ CD10 coexpression on DLBCL (35,50,53). These kinds of B-NHL still remain challenging for flow cytometrists, because the lack of a specific phenotype and their great heterogeneity, especially observed among MZL (nodal, splenic, extranodal), SL and LPL, determine their identification mainly on the j/k ratio.…”

Section: Discussionmentioning

confidence: 55%

Tissue flow cytometry immunophenotyping in the diagnosis and classification of non‐Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases

Demurtas

Stacchini

Aliberti

et al. 2013

Cytometry Part B Clinical

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 55%

Tissue flow cytometry immunophenotyping in the diagnosis and classification of non‐Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases

Demurtas

Stacchini

Aliberti

et al. 2013

Cytometry Part B Clinical

View full text Add to dashboard Cite

“…To the best of our knowledge, there are few reports addressing neuronal genes in hematopoietic malignancies. Considering the fact that CD5 + DLBCL shows many aggressive clinical features 8, frequent central nervous system relapse 9, and poor prognosis 9, we speculated that some of these proteins might be useful as biomarkers for more detailed identification of the aggressive subgroups for DLBCL including CD5 + DLBCL. Thus, to clarify their clinical significance, we performed an immunohistochemical analysis of the relationship between their expressions in DLBCL cells and patients’ clinical features.…”

Section: Introductionmentioning

confidence: 99%

Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B‐cell lymphoma cells and their association with clinical features

et al. 2016

View full text Add to dashboard Cite

Diffuse large B‐cell lymphoma (DLBCL) is clinicopathologically and genetically heterogeneous with variable clinical outcomes. We previously identified signature genes overexpressed in CD5‐positive (CD5+) DLBCL, which is a poor prognostic subgroup of DLBCL. To elucidate the clinical significance of the protein expression of the signature genes overexpressed in CD5+ DLBCL with regard to all DLBCL, not otherwise specified (NOS), 10 genes (SH3BP5,LMO3,SNAP25,SYT5,SV2C,CABP1,FGF1,FGFR2,NEUROD1, and SYN2) were selected and examined immunohistochemically with samples from 28 patients with DLBCL, NOS. Only three protein expressions, SH3BP5, LMO3, and SNAP25, were detected in DLBCL cells and then analyzed further with samples from 187 patients with DLBCL, NOS. The SH3BP5, LMO3, and SNAP25 proteins were expressed in 60% (103/173), 34% (59/175), and 46% (77/168) of DLBCL patients, respectively. These protein expressions were associated with CD5 expression, and only SH3BP5 was frequently expressed in activated B‐cell‐like DLBCL (P = 0.046). Compared to the SH3BP5‐negative group, the SH3BP5+ group was correlated with elderly onset (>60 years, P = 0.0096) and advanced‐stage disease (stage III/IV, P = 0.037). The LMO3+ group showed a worse performance status (>1, P = 0.0004). The SH3BP5+ group and the LMO3+ group had significantly worse overall survival than the negative groups (P = 0.030, 0.034; respectively) for the entire group. In a subgroup analysis of patients treated with rituximab‐containing chemotherapy, there was no significant difference between groups. To the best of our knowledge, this is the first report showing the protein expressions of SH3BP5, LMO3, and SNAP25 in DLBCL cells and their clinical significance in patients with DLBCL. The SH3BP5 and LMO3 protein expressions are associated with the baseline clinical characteristics of DLBCL.

show abstract

“…The reason for this is that this disease is also characterized by a high incidence (13%) of CNS relapse compared with an incidence of approximately 5% for the all patients with DLBCL, even in the rituximab era. 53 Moreover, 83% of the patients who experienced CNS relapse had brain parenchymal disease. More than 60% of patients with CD5 + DLBCL are older than 65 years at diagnosis and would therefore not be eligible for high-dose chemotherapy.…”

Section: Cd5mentioning

confidence: 99%

Treatment of Diffuse Large B-Cell Lymphoma

Miyazaki

2016

JCEH

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) comprises a heterogeneous group with pathophysiological, genetic and clinical features. Many patients can be cured with R-CHOP therapy, which is the current standard regimen. Despite recent progress in improving patient survival, the 40% survival of DLBCL patients remains poor. Therefore, the most important issue for patients with DLBCL remains the development of a new front-line therapy. Several studies have reported that intensified chemotherapy with dose-adjusted EPOCH-R or R-ACVBP was superior to R-CHOP. Gene expression profiling has identified two distinct forms of DLBCL: activated B cell-like (ABC) and germinal center B-cell-like (GCB) types. ABC DLBCL exhibits a worse prognosis than GCB DLBCL by molecular diagnosis after R-CHOP therapy. Next-generation sequencing has identified unique oncogenic mechanisms and genetic complexity, which has provided rational therapeutic targets. There are also a number of biomarkers, including CD5, and prognostic factors. Efforts to distinguish many biomarkers will be crucial for individualized treatment in the future. 〔J Clin Exp Hematop 56(2):79-88, 2016〕

show abstract

CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab

Cited by 111 publications

References 22 publications

Tissue flow cytometry immunophenotyping in the diagnosis and classification of non‐Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases

Tissue flow cytometry immunophenotyping in the diagnosis and classification of non‐Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases

Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B‐cell lymphoma cells and their association with clinical features

Treatment of Diffuse Large B-Cell Lymphoma

Contact Info

Product

Resources

About